NMG
ALDX icon

New Millennium Group’s Aldeyra Therapeutics ALDX Stock Holding History

New Millennium Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,460
Closed -$12.8K – 412
2025
Q3 		$12.8K Buy
+2,460
New +$12.8K 0.01% 203

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

New Millennium Group's ALDX Position: Q4 2025 in Review

New Millennium Group sold out of Aldeyra Therapeutics (ALDX) in Q4 2025, closing a stake of 2,460 shares — an estimated $12.8K sold.

New Millennium Group first reported a position in ALDX in Q3 2025 and held it in 1 quarter. The position peaked at $12.8K in Q3 2025. 135 funds tracked by Wall St. Rank hold ALDX as of Q4 2025.

  • New Millennium Group reported no remaining Aldeyra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • New Millennium Group sold 2,460 Aldeyra Therapeutics shares in Q4 2025, an estimated $12.8K.
  • New Millennium Group first reported a position in Aldeyra Therapeutics in Q3 2025 and held it in 1 quarter.
  • New Millennium Group's Aldeyra Therapeutics position peaked at $12.8K in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.